{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:34:10Z","timestamp":1778499250890,"version":"3.51.4"},"reference-count":91,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Geriatr Psychiatry Neurol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The current comparative efficacy, safety, and acceptability of atypical antipsychotics (AAPs) in treating Parkinson's Disease Psychosis (PDP) are not entirely understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate comparative efficacy, safety, and acceptability of AAPs in patients with PDP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and a network meta-analysis to compare the efficacy, safety, and acceptability of pimavanserin, quetiapine, olanzapine, clozapine, ziprasidone, and risperidone. We estimated relative standardized mean differences (SMDs) for continuous outcomes and odds ratios (OR) for binary outcomes, with their respective 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 19 unique studies evaluating AAPs in a total of 1,242 persons with PDP. Based on Clinical Global Impression Scale for Severity, pimavanserin (SMD, \u22124.81; 95% CI, \u22125.39, \u22124.24) and clozapine (SMD, \u22124.25; 95% CI, \u22125.24, \u22123.26) significantly improved symptoms compared with placebo. Also, compared to placebo, pimavanserin (OR, 1.16; 95% CI, 1.07, 1.24) significantly improved psychotic symptoms based on Scale for Assessment of Positive Symptoms for Parkinson's Disease Psychosis\/Hallucinations and Delusions scores. In comparison to placebo, clozapine (SMD, \u22120.69; 95% CI, \u22121.35, \u22120.02), pimavanserin (SMD, \u22120.01; 95% CI, \u22120.56, 0.53), and quetiapine (SMD, 0.00; 95% CI, \u22120.68, 0.69) did not impair motor function per Unified Parkinson's Disease Rating scale. Based on Mini-Mental State Examination scale, quetiapine (SMD, 0.60; 95% CI, 0.07, 1.14) significantly impaired cognition compared to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with PDP, pimavanserin and clozapine demonstrated significant improvement in psychosis without affecting motor function. With quetiapine being associated with a significant decline in cognition and despite not impairing motor function, our findings suggest that it should be avoided in patients with PDP and reduced cognitive abilities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/08919887231154933","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T19:56:24Z","timestamp":1675194984000},"page":"417-432","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson\u2019s Disease Psychosis: Systematic Review and Network Meta-Analysis"],"prefix":"10.1177","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-8561","authenticated-orcid":false,"given":"Ismaeel","family":"Yunusa","sequence":"first","affiliation":[{"name":"University of South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazia","family":"Rashid","sequence":"additional","affiliation":[{"name":"Acadia Pharmaceuticals, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxanna","family":"Seyedin","sequence":"additional","affiliation":[{"name":"Anlitiks Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepika","family":"Paratane","sequence":"additional","affiliation":[{"name":"Anlitiks Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krithika","family":"Rajagopalan","sequence":"additional","affiliation":[{"name":"Anlitiks Inc."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.1510"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0058-0"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0b013e318278be9b"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23664"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.166"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.11.262"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.389"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000180228.77802.32"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.10.018"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb06891.x"},{"issue":"5","key":"e_1_3_4_12_2","first-page":"S83","article-title":"Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden","volume":"23","author":"Fredericks D","year":"2017","unstructured":"Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 Suppl):S83-S92.","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.3.387"},{"key":"e_1_3_4_14_2","unstructured":"United States Food and Drug Administration. FDA approves first drug to treat hallucinations and delusions associated with Parkinson\u2019s disease. United States Food and Drug Administration website. Approved March 29 2016. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-hallucinations-and-delusions-associated-parkinsons-disease. Published April 29 2016. [Accessed April 26 2022]."},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S201029"},{"key":"e_1_3_4_16_2","unstructured":"Andrew DM Yong M Sandia A et al. Mortality among parkinson\u2019s disease patients treated with pimavanserin or atypical antipsychotics: An observational study in medicare beneficiaries. American Journal of Psychiatry.0(0):appi.ajp.21090876."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjpo.bp.115.000927"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12357"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2020.07.021"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.20m02594"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0706743718816058"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(22)00044-X"},{"key":"e_1_3_4_25_2","unstructured":"Clozapine REMS. What is the Clozapine REMS? https:\/\/www.newclozapinerems.com\/home# Accessed on December 23 2022."},{"issue":"1","key":"e_1_3_4_26_2","first-page":"46","article-title":"Pimavanserin in the treatment of Parkinson's Disease Psychosis: Meta-analysis and meta-regression of randomized clinical trials","volume":"19","author":"Mansuri Z","year":"2022","unstructured":"Mansuri Z, Reddy A, Vadukapuram R, Trivedi C, Amara A. Pimavanserin in the treatment of Parkinson's Disease Psychosis: Meta-analysis and meta-regression of randomized clinical trials. Innov Clin Neurosci. 2022;19(1-3):46-51.","journal-title":"Innov Clin Neurosci"},{"key":"e_1_3_4_27_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2022","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. www.training.cochrane.org\/handbook."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4"},{"key":"e_1_3_4_29_2","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013","unstructured":"Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Association; 2013."},{"issue":"7","key":"e_1_3_4_30_2","first-page":"28","article-title":"The clinical global impressions scale: Applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: Applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.","journal-title":"Psychiatry (Edgmont)"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21875"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-374105-9.00091-5"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1037"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500402"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1167"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2017.01.943"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6188"},{"issue":"12","key":"e_1_3_4_43_2","first-page":"700","article-title":"Interpreting estimates of treatment effects: implications for managed care","volume":"33","author":"Faraone SV","year":"2008","unstructured":"Faraone SV. Interpreting estimates of treatment effects: implications for managed care. P T. 2008;33(12):700-711.","journal-title":"P T"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000366428"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1045"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1761"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.02.009"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076654"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852917000736"},{"key":"e_1_3_4_52_2","article-title":"Pimavanserin for the treatment of Alzheimer\u2019s Disease Psychosis: An evaluation of the clinical importance of efficacy results","author":"Ballard C","year":"2022","unstructured":"Ballard C, Cummings J, Tariot PN, Pathak S, Coate B, Stankovic S. Pimavanserin for the treatment of Alzheimer\u2019s Disease Psychosis: An evaluation of the clinical importance of efficacy results. medRxiv. 2022:2022.2008.2011.22278482.","journal-title":"medRxiv"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01392-6"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.12.3.364"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.3109\/00207450903222758"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(00)00024-9"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.789"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.176"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000236769.31279.19"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000136891.17006.ec"},{"key":"e_1_3_4_62_2","volume-title":"A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","author":"Inc AP","unstructured":"Inc AP. A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis. https:\/\/ClinicalTrials.gov\/show\/NCT00477672. Published 2009. Updated June. Accessed."},{"key":"e_1_3_4_63_2","volume-title":"A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","author":"Inc AP","unstructured":"Inc AP. A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis. https:\/\/ClinicalTrials.gov\/show\/NCT00658567. Published 2009. Updated December. Accessed."},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.2-150.v1"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10217"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20474"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31824d5115"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.029868"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21116"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S5335"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199903113401003"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27488"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00087"},{"key":"e_1_3_4_74_2","unstructured":"FDA. FDA is temporarily exercising enforcement discretion with respect to certain Clozapine REMS program requirements to ensure continuity of care for patients taking clozapine. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-temporarily-exercising-enforcement-discretion-respect-certain-clozapine-rems-program. Published 2021. Updated 12\/02\/2021. Accessed May 19 2022."},{"key":"e_1_3_4_75_2","unstructured":"Affairs DoV. VA national clozapine registry. Department of Veterans Affairs. https:\/\/catalog.data.gov\/dataset\/va-national-clozapine-registry. Published 2021. Updated April 21 2021. Accessed May 19 2022."},{"key":"e_1_3_4_76_2","unstructured":"National Institute for Health and Care Excellence (NICE) guideline [NG71]. Parkinson\u2019s disease in adults. NICE 2017. https:\/\/www.nice.org.uk\/guidance\/ng71\/chapter\/Recommendations#pharmacological-management-of-non-motor-symptoms. Accessed May 15 2022."},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1951"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-018-0055-3"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-319008"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27902"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27488"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002670"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.181504"},{"key":"e_1_3_4_84_2","unstructured":"NUPLAZID. Prescribing information. Acadia Pharmaceuticals Inc. https:\/\/www.nuplazidhcp.com\/pdf\/nuplazid-prescribing-information.pdf. Accessed December 23 2022."},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S324145"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15767"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu145"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-138"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12101286"},{"key":"e_1_3_4_90_2","first-page":"225","volume-title":"Users\u2019 guides to the medical literature: a manual for evidence-based clinical practice","author":"Brozek J","year":"2008","unstructured":"Brozek J, Falavigna M. What determines the width of the confidence interval. Users\u2019 guides to the medical literature: a manual for evidence-based clinical practice New York: McGraw-Hill. 2008:225-231."},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0473-z"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-015-0060-8"}],"container-title":["Journal of Geriatric Psychiatry and Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08919887231154933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08919887231154933","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08919887231154933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:16:43Z","timestamp":1777501003000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08919887231154933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1177\/08919887231154933"],"URL":"https:\/\/doi.org\/10.1177\/08919887231154933","relation":{},"ISSN":["0891-9887","1552-5708"],"issn-type":[{"value":"0891-9887","type":"print"},{"value":"1552-5708","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}